Takeda Pharmaceutical Co. Ltd.
Company Snapshot
Company Overview
Takeda Pharmaceutical Co. Ltd. is a global biopharmaceutical company headquartered in Japan. Takeda focuses on five key business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapeutics (PDT) Immunology, Oncology and Neuroscience. Takeda supports dedicated R&D efforts across three areas: Innovative Biopharma, PDT and Vaccines.
In January 2019, Takeda acquired Shire for an aggregate consideration of $62 billion. The acquisition of Shire significantly changed its business through, among other things, the significant expansion of its product portfolio and geographic presence.
Takeda supports dedicated R&D efforts across three areas: Innovative Biopharma, PDT, and Vaccines. The company operates over 200 collection centers globally and has eight manufacturing plants. BioLife, a part of Takeda, is the company's global plasma collection network. In January 2019.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Takeda Pharmaceutical Co. Ltd. In News
Company's Business Segments
- Gastroenterology (GI) : Ulcerative colitis or Crohn’s disease, Refractory complex perianal fistulas.
- Rare Diseases : Prevention of hereditary angioedema attacks, Post-transplant CMV infection.
- PDT immunology : Primary and secondary immunodeficiencies and multifocal motor neuropathy, Hypovolemia, hypoalbuminemia.
- Oncology : ALK-positive non-small cell lung cancer
- Others : Dengue diseas, Active immunization, COVID-19 and others
Applications/End User Industries
- Immunology
- Oncology
- Gastrointestinal
- Inflammatory Bowel
- Orphan
- Rare Genetic Disorders
- Plasma-Derived Therapies
- Immune System
- Autoimmune
- Oncology Therapies
- Chemotherapies
- Immunotherapies
- Pharmaceutical Research
